Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Trial to Assess the Safety, Immunogenicity and Preliminary Efficacy of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Administered to Patients With Non-Small-Cell Lung Cancer (NSCLC) After Receiving Conventional First Line Chemotherapy

NCT00516685 is registered in ClinicalTrials.gov with Bioven Sdn. Bhd. as lead sponsor.

NCT NCT00516685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00516685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Trial to Assess the Safety, Immunogenicity and Preliminary Efficacy of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Administered to Patients With Non-Small-Cell Lung Cancer (NSCLC) After Receiving Conventional First Line Chemotherapy
Lead sponsor
Bioven Sdn. Bhd.
Phase
Phase 2/3
Overall status
Terminated
Start date
July 31, 2007
Completion date
Not reported
Enrollment
230 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer (nsclc) stage iiib/iv